Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Many developers and innovators are working on a wide variety of apps to improve healthcare and lower costs. Some have seen impressive success while others are running afoul of federal regulators.
The uninsured rate fell to 13.8 percent last year, the lowest annualized rate in the seven years of the Gallup-Healthways Well-Being Index measurement.
Researchers from the University of Minnesota School of Public Health identified seven common aspects for successful internet-based intervention programs in a study published in the Journal of Internet Medical Research.
About three-quarters of providers are ready to start meeting Medicare’s chronic care management program requirements within the next six months, according to a survey by Kryptik, a software company focusing on population health management.
Nurses using mobile devices loaded with a custom app prompting evidence-based guidelines were significantly more likely to identify health issues such as obesity, smoking, and depression during routine exams.
The University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC) have entered into an agreement designed to accelerate the commercialization of intellectual property arising from the research activity of university faculty.
With the shift toward more outpatient care and an emphasis on limiting readmissions, hospitals are shrinking capacity or closing, Modern Healthcare reports.
Members of the Ohio Children's Hospitals' Solutions for Patient Safety have prevented serious harm in nearly 230 patients and eliminated nearly $6 million from the states healthcare system over the past three years.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
